



Regulation of the Hypoxic Response by Noncoding RNA

Guest Editor:

Dr. Rafał Bartoszewski

Department of Biophysics,
Faculty of Biotechnology,
University of Wrocław, F. Joliot-
Curie 14a Street, 50-383 Wrocław,
Poland

Deadline for manuscript
submissions:

closed (31 October 2024)

Message from the Guest Editor

Hypoxia activates the fast global reprogramming of gene expression in order to secure survival and to restore oxygen homeostasis. However, although the Hypoxia Inducible Factors (HIFs) have been recognized as master regulators of hypoxic response, specific disease-oriented therapeutic modulation of their activity remains very challenging. Notably, recent studies defined novel noncoding RNA-based mechanisms that provide a hypoxic response with novel regulatory circuits and thus therapeutic opportunities. MicroRNAs, long noncoding RNAs, piRNA, and other RNA molecules can efficiently shape the course and effects of HIF activity and consequently decide the fate of hypoxic cells.

This Special Issue focuses on both the biological and therapeutic role of noncoding RNA in governing cell signaling and fate under hypoxia or ischemia.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)